Sygnature Discovery

Integrated drug discovery

Sygnature Discovery describes its model as truly integrated drug discovery, with co-located teams moving compounds from target identification to candidate.

• Target identification and validation: AI-supported platform combined with expert insight and laboratory validation.
• Hit identification and hit-to-lead: validated hits and early proof-of-concept work, de-risked and profiled before lead optimization.
• Lead optimization: advancing leads toward clinical candidates.

Scientific solutions

The site lists capabilities in computer-aided drug design (including structure-based and ligand-based design, virtual screening, ADMET prediction and generative AI/machine learning), protein science and structural biology (including antibodies and biotherapeutics, X-ray crystallography, cryo-EM and NMR), chemistry, drug metabolism and pharmacokinetics, in vivo pharmacology, and form and formulation.

Scale and reach

The About page states 700+ scientists from over 50 countries and 60+ advanced candidates. The company describes partnering with biotech and pharma across the US, Canada, the UK and Europe, with UK and Canada sites.